Half-life is one of those concepts that gets thrown around a lot in peptide research without much explanation of what it actually means in practice. Understanding it properly changes how you think about dosing frequency — and it explains why two researchers using the same compound and total daily dose can get completely different results simply because of when they administer it.
What Half-Life Means in Plain Language
A compound is half-life is the time it takes for the concentration in the bloodstream (or relevant tissue) to fall to half its peak level. After one half-life, 50% remains. After two half-lives, 25%. After three, about 12.5%. After roughly five half-lives, the compound has cleared to below 3% of the original level — generally considered effectively cleared.
This matters because most peptides need to be present at or above a minimum effective concentration to produce the research effect you are studying. Fall below that threshold and the compound is not doing much. Exceed it significantly and you risk side effects or receptor downregulation.
Short Half-Life Compounds: Frequent Dosing Required
Some peptides have half-lives measured in minutes rather than hours. Growth hormone releasing peptides like GHRP-2 and GHRP-6, for example, have half-lives of around 15-30 minutes. At that speed, a single daily administration means the compound is effectively cleared within a couple of hours. Researchers studying sustained effects with such compounds typically administer multiple times per day.
This is also why timing relative to food intake matters for certain peptides. Consuming a large carbohydrate or fat-rich meal before administration of some GH-releasing compounds can blunt the research response because the body is already in a different hormonal state.
Longer Half-Life Compounds: More Flexibility
On the other end of the spectrum, GLP-1 analogues like semaglutide have been engineered specifically to have very long half-lives — semaglutide sits around 7 days. This is by design, allowing once-weekly administration in clinical settings. For research purposes, this long half-life means the compound accumulates in the system over several weeks before reaching steady state, which has implications for how quickly you see effects and how long washout takes after the research period ends.
Steady State: The Concept That Changes Everything
Here is what most basic half-life explanations miss: steady state. When you administer a compound repeatedly, each dose adds to what is left from the previous dose. Steady state is the point at which the amount being eliminated between doses equals the amount being added with each new dose. This typically occurs after 4-5 half-lives worth of repeated dosing.
For a peptide with a 4-hour half-life dosed twice daily, steady state arrives within roughly 24-48 hours. For semaglutide with its 7-day half-life, steady state is not reached until 4-5 weeks into the protocol. This is why GLP-1 research studies typically have a dose-escalation phase — not just for tolerability, but because the effective concentration is still climbing during those early weeks.
Using a Half-Life Calculator for Dosing Intervals
Working out the optimal dosing interval by hand involves logarithmic calculations that are easy to get wrong. A half-life calculator takes the compound is half-life value and your target dosing interval and tells you what percentage of the compound remains at the time of the next dose. This helps you design protocols where you are maintaining meaningful coverage without excessive accumulation.
As a general rule: for compounds with half-lives under 2 hours, plan for multiple daily administrations if sustained research effects are the goal. For half-lives of 4-12 hours, once or twice daily is typical. For half-lives above 24 hours, less frequent administration is appropriate and excessive frequency will cause accumulation.
The Practical Takeaway
Half-life is not just a pharmacokinetic number to note and forget. It determines your dosing schedule, shapes how long it takes to see effects, and tells you how long the research window actually lasts after the last administration. Spend a few minutes calculating it properly before designing any protocol and you will avoid one of the most common sources of inconsistency in peptide research.